ADVERTISEMENT FEATURE ADVERTISER RETAINS SOLE RESPONSIBILITY FOR CONTENT ImmunoPrecise Antibodies Ltd. www.immunoprecise.com Single source provider of full-service therapeutic antibody development ImmunoPrecise offers a comprehensive suite of solutions to rapidly deliver high-performing therapeutic antibodies. ImmunoPrecise Antibodies (IPA) is an innovation- driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. IPA aims to transform the conventional, multi-vendor, product development model by bringing advanced high-throughput, data-driven technologies to its partners. IPA incorporates the advantages of diverse antibody repertoires with its therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes. Operating from state-of-the-art laboratories located in Victoria, British Columbia, and in Oss and Utrecht in the Netherlands, the company brings resourceful solutions, adaptable approaches, and insightful collaboration to every program. IPA’s single-source model, fast turn-around, and >95% success rate can greatly accelerate the critically important research of its global partners (Fig. 1). The expertise of IPA’s dedicated technical team assures optimal work plans are followed for the discovery and development of custom, high-performing therapeutic antibodies. A comprehensive suite of antibody discovery services ImmunoPrecise’s broad range of capabilities can seamlessly take a program from concept to (pre) clinic and allows for discovery in a wide range of species and strains that include rabbit, llama, human, and wild-type and transgenic mouse, rat and chicken models. Some of the most in-demand technologies are IPA’s unique immunization methods, the proprietary B cell Select and DeepDisplay discovery platforms, and robust, efficient antibody engineering and optimization protocols. • Immunization technologies utilized include three genetic immunization options—gene gun, dermal tattooing, and hydrodynamic tail vein (HTV) injection—as well as whole cell immunization (ModiVacc) and an accelerated RapidPrime program. • B cell Select allows the screening of an animal’s entire immune repertoire and the selection of a desired antibody directly from B cells for earlier hit identification from a more diverse panel of antibodies compared with traditional technologies. Screening the entire population of B cells optimizes throughput and success rates while maintaining native heavy and light chain pairings. • DeepDisplay is based upon the selection of antigen-specific recombinant antibody fragments from custom immune libraries from multiple species in a single-chain variable fragment (scFv) or single-domain antibody (VHH) format. Partners also have access to the IPA’s proprietary in-house disease and naïve human or llama phage libraries. • ImmunoPrecise’s affinity maturation service can improve antibody affinities significantly, while the humanization approach results in antibodies with retained affinity and specificity. Additional, complementary services that round out the company’s end-to-end service model include protein expression and purification using the proprietary rPEx platform, affinity maturation, antibody characterization and optimization, developability studies, stable cell line development and cryopreservation services and storage. Personalized antibody development With more than 30 years of antibody development and protein manufacturing experience, and thousands of successful projects, IPA understands the importance of strong project management and communication skills. Skilled scientists develop custom, tailored programs to meet client needs and budgets, while designated project managers directly communicate and share data with the partner using secure, cloud-based platforms with 24/7 access. “Our infrastructure and experience in antibody discovery and protein manufacturing together with our streamlined project management enables us to help ensure our partners’ success, no matter how challenging the disease or target,” said Stefan Lang, CBO of IPA. Partnering: leveraging the power of IPA services for antibody discovery Talem Therapeutics, an ImmunoPrecise company, is focused on the discovery and development of next-generation, fully-human, monoclonal therapeutic antibodies to target multiple disease indications. Talem aims to accelerate novel, high-value, therapeutic antibody treatments to the clinic, by leveraging direct access to IPA’s proprietary antibody discovery platforms and innovative technologies to rapidly develop products with greater chances of success. Talem has created a diverse internal pipeline and is open for flexible partnership and out-licensing opportunities. Fig. 1 | ImmunoPrecise’s single-source suite of solutions. IPA’s single-source, open-access biologics technology platform offers end-to-end solutions, empowering partners to discover and develop biologics from concept to clinical lead. Stefan Lang, CBO ImmunoPrecise Antibodies Ltd. Victoria, BC, Canada Tel: +1-250-483-0308 Email: [email protected] CONTACT “ Our infrastructure and experience in antibody discovery and protein manufacturing together with our streamlined project management enables us to help ensure our partners’ success, no matter how challenging the disease or target Stefan Lang, CBO, ImmunoPrecise Antibodies www.nature.com/biopharmdeal | September 2021 | B35
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
A D V E R T I S E M E N T F E A T U R E
A D V E R T I S E R R E TA I N S S O L E R E S P O N S I B I L I T Y F O R C O N T E N T
ImmunoPrecise Antibodies Ltd.www.immunoprecise.com
Single source provider of full-servicetherapeutic antibody developmentImmunoPrecise offers a comprehensive suite of solutions to rapidly deliver high-performing therapeutic antibodies.
ImmunoPrecise Antibodies (IPA) is an innovation-driven, technology platform company thatsupports its pharmaceutical and biotechnologycompany partners in their quest to discover anddevelop novel, therapeutic antibodies against allclasses of disease targets.
IPA aims to transform the conventional,multi-vendor, product development model bybringing advanced high-throughput, data-driventechnologies to its partners. IPA incorporatesthe advantages of diverse antibody repertoireswith its therapeutic antibody discovery suiteof technologies, to exploit antibodies of broadepitope coverage, multiple antibody formats,valency and size, and to discover antibodiesagainst multiple/rare epitopes.
Operating from state-of-the-art laboratorieslocated in Victoria, British Columbia, and in Ossand Utrecht in the Netherlands, the companybrings resourceful solutions, adaptableapproaches, and insightful collaboration toevery program. IPA’s single-source model, fastturn-around, and >95% success rate can greatlyaccelerate the critically important research ofits global partners (Fig. 1). The expertise ofIPA’s dedicated technical team assures optimalwork plans are followed for the discovery anddevelopment of custom, high-performingtherapeutic antibodies.
A comprehensive suite ofantibody discovery servicesImmunoPrecise’s broad range of capabilities canseamlessly take a program from concept to (pre)clinic and allows for discovery in a wide rangeof species and strains that include rabbit, llama,human, and wild-type and transgenic mouse, ratand chicken models.
Some of the most in-demand technologiesare IPA’s unique immunization methods, theproprietary B cell Select and DeepDisplaydiscovery platforms, and robust, efficient antibodyengineering and optimization protocols.• Immunization technologies utilized include
three genetic immunization options—genegun, dermal tattooing, and hydrodynamic tailvein (HTV) injection—as well as whole cellimmunization (ModiVacc) and an acceleratedRapidPrime program.
• B cell Select allows the screening of an animal’sentire immune repertoire and the selection ofa desired antibody directly from B cells forearlier hit identification from a more diversepanel of antibodies compared with traditionaltechnologies. Screening the entire population
of B cells optimizes throughput and successrates while maintaining native heavy and lightchain pairings.
• DeepDisplay is based upon the selectionof antigen-specific recombinant antibodyfragments from custom immune libraries frommultiple species in a single-chain variablefragment (scFv) or single-domain antibody(VHH) format. Partners also have access to theIPA’s proprietary in-house disease and naïvehuman or llama phage libraries.
• ImmunoPrecise’s affinity maturation service canimprove antibody affinities significantly, whilethe humanization approach results in antibodieswith retained affinity and specificity.
Additional, complementary services that roundout the company’s end-to-end service modelinclude protein expression and purificationusing the proprietary rPEx platform, affinitymaturation, antibody characterization andoptimization, developability studies, stable cellline development and cryopreservation servicesand storage.
Personalized antibody developmentWith more than 30 years of antibody developmentand protein manufacturing experience, andthousands of successful projects, IPA understandsthe importance of strong project management andcommunication skills. Skilled scientists developcustom, tailored programs to meet client needsand budgets, while designated project managersdirectly communicate and share data with thepartner using secure, cloud-based platformswith 24/7 access. “Our infrastructure andexperience in antibody discovery and proteinmanufacturing together with our streamlinedproject management enables us to help ensure ourpartners’ success, no matter how challenging thedisease or target,” said Stefan Lang, CBO of IPA.
Partnering: leveraging the power ofIPA services for antibody discoveryTalem Therapeutics, an ImmunoPrecise company,is focused on the discovery and developmentof next-generation, fully-human, monoclonaltherapeutic antibodies to target multiple diseaseindications. Talem aims to accelerate novel,high-value, therapeutic antibody treatmentsto the clinic, by leveraging direct access toIPA’s proprietary antibody discovery platformsand innovative technologies to rapidly developproducts with greater chances of success. Talemhas created a diverse internal pipeline and isopen for flexible partnership and out-licensingopportunities.
Fig. 1 | ImmunoPrecise’s single-source suite of solutions. IPA’s single-source, open-access biologicstechnology platform offers end-to-end solutions, empowering partners to discover and develop biologicsfrom concept to clinical lead.
Stefan Lang, CBOImmunoPrecise Antibodies Ltd.Victoria, BC, CanadaTel: +1-250-483-0308Email: [email protected]
CON
TACT
“Our infrastructure andexperience in antibody
discovery and proteinmanufacturing together withour streamlined projectmanagement enables us tohelp ensure our partners’success, no matter howchallenging the disease ortarget
Stefan Lang, CBO,ImmunoPrecise Antibodies
www.nature.com/biopharmdeal | September 2021 | B35
Related Documents
